<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Santella B</submitter><funding>PNRR-MUR NextGenerationEU PRIN-PNRR 2022</funding><funding>PNRR-MUR NextGenerationEU PRIN 2022</funding><funding>National Biodiversity Future Center</funding><pagination>265</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12911300</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>lipedema is a chronic, progressive adipose disorder predominantly affecting women, characterized by painful, symmetrical subcutaneous fat accumulation, and typically resistant to lifestyle interventions. The pathophysiology of advanced-stage lipedema remains poorly defined, and no validated biomarkers or targeted therapies are currently available.&lt;h4>Methods&lt;/h4>in this observational study, we applied a comprehensive multi-omics approach to dissect the molecular and metabolic alterations underlying late-stage lipedema.&lt;h4>Results&lt;/h4>Genome-wide DNA methylation profiling identified over 5,000 differentially methylated CpG sites affecting genes involved in receptor tyrosine kinase signaling, phospho-metabolism, and immune pathways. Transcriptomic analysis revealed profoun</pubmed_abstract><journal>Journal of translational medicine</journal><pubmed_title>Epigenetic alterations of AKT1 orchestrate a metabolic reprogramming in advanced lipedema: translational insights from an integrated multi-omics study.</pubmed_title><pmcid>PMC12911300</pmcid><funding_grant_id>CN00000033</funding_grant_id><funding_grant_id>D53D23007790001</funding_grant_id><funding_grant_id>D53D23016530001</funding_grant_id><pubmed_authors>Schiavo L</pubmed_authors><pubmed_authors>Salvati A</pubmed_authors><pubmed_authors>Nassa G</pubmed_authors><pubmed_authors>Memoli D</pubmed_authors><pubmed_authors>Marino C</pubmed_authors><pubmed_authors>Pulai C</pubmed_authors><pubmed_authors>D'Elia M</pubmed_authors><pubmed_authors>D'Ursi A</pubmed_authors><pubmed_authors>Mingo M</pubmed_authors><pubmed_authors>Santella B</pubmed_authors><pubmed_authors>Papp A</pubmed_authors><pubmed_authors>Rastrelli L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Epigenetic alterations of AKT1 orchestrate a metabolic reprogramming in advanced lipedema: translational insights from an integrated multi-omics study.</name><description>&lt;h4>Background&lt;/h4>lipedema is a chronic, progressive adipose disorder predominantly affecting women, characterized by painful, symmetrical subcutaneous fat accumulation, and typically resistant to lifestyle interventions. The pathophysiology of advanced-stage lipedema remains poorly defined, and no validated biomarkers or targeted therapies are currently available.&lt;h4>Methods&lt;/h4>in this observational study, we applied a comprehensive multi-omics approach to dissect the molecular and metabolic alterations underlying late-stage lipedema.&lt;h4>Results&lt;/h4>Genome-wide DNA methylation profiling identified over 5,000 differentially methylated CpG sites affecting genes involved in receptor tyrosine kinase signaling, phospho-metabolism, and immune pathways. Transcriptomic analysis revealed profoun</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-16T04:58:59.865Z</modification><creation>2026-07-09T13:10:03.058Z</creation></dates><accession>S-EPMC12911300</accession><cross_references><pubmed>41580786</pubmed><doi>10.1186/s12967-026-07726-w</doi></cross_references></HashMap>